title: [Comparative analysis of mechanical and biological prosthetic valves after isolated valve replacement--cooperative study on total 1281 patients].
abstract: A total of 1281 patients (594 aortic and 687 mitral) received 734 mechanical valves (320 Björk-Shiley, 283 SJM and 131 Omniscience) and 547 biological (259 ionescu-Shiley, 227 Hancock, and 61 Carpentier-Edwards) were analyzed for postoperative valve dysfunction and thromboembolism. The actuarial survival rates (free from late cardiac deaths and valve-related deaths) were 88.6% (11 years) for mechanical mitral and 86.0% (11 years) for biological mitral valves, and 91.7% (16 years) and 88.5% (12 years), for mechanical and biological aortic valves, respectively. There were no significant differences among these groups. Actuarial rates of freedom from valve-related events were 88.7% (11 years) and 51.7%, for mechanical and biological mitral valves, respectively. There was significant difference between the two types of valves in over 7 years after surgery. In contrast, there were no significant differences between mechanical and biological aortic valves. Actuarial rates of freedom from valve dysfunction were 97.6% (11 years) for mechanical and 56.5% (12 years) for biological mitral valves. The net 12 year results showed no significant differences between the two types of mitral prosthetic valves, but a significantly increased rate of valve dysfunction in the biological mitral valves compared with the mechanical in over 6 years of the study. Concerning AVR, there were no significant differences in the incidence of valve dysfunction between mechanical and biological aortic valves. Actuarial rates of freedom thromboembolism were 92.3% (11 years) and 93.8% (11 years) for mechanical and biological mitral valves, respectively. There were no significant differences between the two types of mitral prosthetic valves.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: S
authors.initials: S
authors.lastname: Nakano
authors.forename: Y
authors.initials: Y
authors.lastname: Kawashima
authors.forename: S
authors.initials: S
authors.lastname: Komatsu
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: S
authors.initials: S
authors.lastname: Eguchi
authors.forename: M
authors.initials: M
authors.lastname: Aosaki
authors.forename: T
authors.initials: T
authors.lastname: Misaki
authors.forename: K
authors.initials: K
authors.lastname: Ohara
authors.forename: K
authors.initials: K
authors.lastname: Tokunaga
mesh_terms: D001021:Aortic Valve; D001705:Bioprosthesis / Q000401:mortality*; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000401:mortality*; D006801:Humans; D007564:Japan; D008943:Mitral Valve; D015337:Multicenter Studies as Topic; D011183:Postoperative Complications / Q000453:epidemiology; D011379:Prognosis; D011475:Prosthesis Failure; D013923:Thromboembolism / Q000453:epidemiology